Prognostic and Predictive Role of Angiogenic Markers in Non- Small Cell Lung Cancer

Objective: Despite the existence of detailed consensus guidelines, challenges remain regarding the role angiogenetic factors on non-small cell lung cancer (NSCLC). This study was conducted to determine the role of the vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin2 (Ang2) in patients with NSCLC. Methods: This study included 64 consecutive patients with non-small cell lung cancer, who admitted to clinic. Pre-treatment serum VEGF, IL-8 and Ang2 levels were evaluated. Patients were treated according to internationally accepted guidelines. Results: VEGF and IL-8 serum levels of patients with both squamous cell carcinoma and adenocarcinoma were significantly higher than controls (p<0.05). In addition, IL-8 levels were lower among treatment-responders than non-responders (p:0.031). Impact of elevated or decreased levels of VEGF, Ang2 and IL-8 on survival was evaluated, accepting median level as reference. There was no correlation between the serum levels of VEGF, Ang2, IL-8 and survival. Conclusion: We found that the levels of angiogenic markers were significantly different between non-small cell lung cancer patients and controls. These markers could elicit more information related to stage and prognosis.

• Publication year

  2019

• Venue

  Asian Pacific Journal of Cancer Prevention

• Publication date

  2019-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.31557/APJCP.2019.20.3.733PMID 30909672PMCID 6825760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-8 in cancer pathogenesis, treatment and follow-up.

  2017cited by this paper
• Tumor angiogenesis and vascular normalization: alternative therapeutic targets

  2017cited by this paper
• Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions

  2017influential reference
• CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3–72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis

  2015cited by this paper
• The Interleukin-8 Pathway in Cancer

  2008influential reference
• Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis

  2006influential reference
• Serum Vascular Endothelial Growth Factor (VEGF) and Bcl-2 Levels in Advanced Stage Non-Small Cell Lung Cancer

  2006influential reference
• The intratumoral expression of vascular endothelial growth factor and interleukin‐8 associated with angiogenesis in nonsmall cell lung carcinoma patients

  2001cited by this paper
• Clinical implications of circulating angiogenic factors in cancer patients.

  2001cited by this paper
• Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer.

  2000cited by this paper
• Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.

  1996cited by this paper
• Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma

  1994cited by this paper
• Interleukin-8 as a macrophage-derived mediator of angiogenesis.

  1992cited by this paper
• Tumor

  1828cited by this paper
• This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License

  year unknowncited by this paper

• Association between serum levels of 12 different cytokines and short-term efficacy of chemoradiotherapy in esophageal squamous cell carcinoma

  2025cites this paper
• Dynamics of VEGF-А, Аngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery

  2025cites this paper
• Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC

  2023cites this paper
• The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer

  2022cites this paper
• The Clinical Importance of IL-6, IL-8, and TNF-α in Patients with Ovarian Carcinoma and Benign Cystic Lesions

  2021cites this paper
• Circulating cytokines associated with clinical outcomes in advanced non‐small cell lung cancer patients who received chemoimmunotherapy

  2021cites this paper
• Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.

  2020cites this paper
• [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].

  2020cites this paper
• Long noncoding RNA PSMA3-AS1 functions as a microRNA-409-3p sponge to promote the progression of non-small cell lung carcinoma by targeting spindlin 1

  2020cites this paper
• Changes in serum inflammatory factors, adiponectin, intestinal flora and immunity in patients with non-small cell lung cancer.

  2020cites this paper
• Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non‐small cell lung cancer by regulating miR‐449a/TGIF2 axis

  2019cites this paper
• Cyclophilin B promotes cell proliferation, migration, invasion and angiogenesis via regulating the STAT3 pathway in non-small cell lung cancer.

  2019cites this paper
• World Journal of Clinical Oncology

  year unknowncites this paper